Wooree Group Pushes for Scientific Standards in Liposome Market

At a trade show in Bangkok this September, the head of a South Korean biotech company made a simple but pointed argument: the liposome market has grown fast, but nobody has agreed on what actually makes a liposome real. Ji-yong Yoon, CEO of Wooree Group, stood before an industry audience and said the problem was obvious. Some manufacturers slap the word "liposomal" on a product just because they measured particle size or added phospholipids. That's not enough. "Scientific validation should come before a product is labeled 'liposomal,'" Yoon said.

Wooree Group has spent six decades in biotechnology and lighting. The company positions itself as Korea's first to commercialize liposomal health functional foods at scale. At Vitafoods Asia 2026, held September 2-4 in Bangkok, the company displayed its full operation: Wooree Green Science handles raw ingredients, Wooree Bio manages manufacturing, and two consumer brands—Harutin and Clarion—sell the finished products. The booth itself won a Silver Award for sustainable design, built from reusable materials and engineered to minimize waste.

Yoon's central concern is that the market lacks any shared standard for quality. Without one, companies compete on marketing claims rather than actual performance. He proposed what he calls the "Six Pillars"—a validation framework that would require any product claiming to be liposomal to pass through six distinct tests. First, cryo-transmission electron microscopy would verify that liposomes actually formed. Second, nanoparticle tracking analysis would measure particle size, distribution, and concentration. Third, the manufacturer would have to prove encapsulation efficiency—that the active ingredient actually stayed inside the liposome. Fourth, the product would need to demonstrate long-term shelf stability. Fifth, it would have to survive the gastrointestinal tract without breaking down prematurely. Sixth, pharmacokinetic evaluation would show whether the liposome actually improved bioavailability—whether the body could absorb and use the ingredient better than it could without the liposome.

This is not theoretical. Wooree Green Science has built a proprietary ingredient line called LIPOPRIME, which wraps approximately 40 different compounds—Vitamin C, glutathione, omega-3, curcumin—in liposomal form. When the company ran nanoparticle tracking analysis on select LIPOPRIME ingredients, it found particle concentrations up to 24 times higher than competing products already on the market. That gap suggests either that competitors are not measuring accurately, or that they are not actually delivering what they claim.

Yoon's argument amounts to a business strategy dressed as industry advocacy. If Wooree Group can convince the market that rigorous validation is the price of entry, the company's own validated products become more valuable. Competitors who have not invested in the Six Pillars framework would face pressure to do so or lose credibility. It is a way to turn scientific rigor into competitive advantage.

The company is already moving beyond the trade show circuit. Wooree Group has begun selling test products from Harutin, its health functional food brand, on Amazon in the United States. It is also partnering with a plant-cell biotechnology firm to develop next-generation functional ingredients. The stated plan is to expand through Southeast Asia and into the broader global nutraceutical market. If the Six Pillars framework gains traction—if industry bodies, regulators, or retailers begin to demand it—Wooree Group's early investment in validation becomes a structural advantage. The liposome market is growing. The question now is whether it will grow with standards, or whether it will remain a space where the word "liposomal" means whatever a company wants it to mean.